BLFS on Nasdaq
BIOLIFE SOLUTIONS INC
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with VASO Corp, Ceribell, Inc. or Outset Medical, Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
64.6%Gross margin3
-17.3%Operating margin3
-4.8%Net margin3
28.9%Revenue growth, 20253
-1.2%Return on equity3
0.00×Debt to equity3
$10.6MFree cash flow3
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue35¢$34.1M
- Research and development8¢$7.6M
- Other costs57¢$54.5M
- Income tax0¢$49.0K
Out of $96.2M in revenue.3 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Capital spending47¢$9.5M
- Kept or used elsewhere53¢$10.6M
Out of $20.1M of cash from operations.3
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | $96.2M | $74.6M | $68.0M |
| Cost of revenue | $34.1M | $24.6M | $26.7M |
| Gross profit | $62.1M | $50.1M | $41.3M |
| General and administrative | $45.5M | $40.6M | $42.8M |
| Sales and marketing | $9.8M | $8.9M | $11.4M |
| Research and development | $7.6M | $4.8M | $5.5M |
| IPR&D expense | $15.5M | $0 | $0 |
| Intangible asset amortization | $263.0K | $263.0K | $1.0M |
| Change in fair value of contingent consideration | $0 | $0 | -$2.2M |
| Total operating expenses | $78.7M | $54.6M | $58.5M |
| Operating loss | -$16.6M | -$4.5M | -$17.2M |
| Interest income (expense), net | $2.7M | -$766.0K | -$1.4M |
| Other income | $1.8M | $494.0K | $1.3M |
| Change in fair value of investments | $0 | -$4.1M | $0 |
| Gain on settlement of Global Cooling escrow | $0 | $0 | $5.1M |
| Total other income (expense), net | $4.5M | -$4.3M | $5.0M |
| Loss from continuing operations before income tax expense (benefit) | -$12.1M | -$8.8M | -$12.2M |
| Income tax expense (benefit) | $49.0K | -$38.0K | -$64.0K |
| Loss from continuing operations | -$12.1M | -$8.8M | -$12.2M |
| Income (loss) from discontinued operations before income tax expense | $7.5M | -$11.3M | -$55.6M |
| Income tax expense | $0 | $132.0K | $233.0K |
| Income (loss) from discontinued operations | $7.5M | -$11.4M | -$55.8M |
| Net loss | -$4.6M | -$20.2M | -$68.0M |
| Continuing operations (in dollars per share) | -$0 | -$0 | -$0 |
| Discontinuing operations (in dollars per share) | $0 | -$0 | -$1 |
| Net loss (in dollars per share) | -$0.09 | -$0.44 | -$1.55 |
| Continuing operations (in dollars per share) | -$0 | -$0 | -$0 |
| Discontinuing operations (in dollars per share) | $0 | -$0 | -$1 |
| Net loss (in dollars per share) | -$0.10 | -$0.44 | -$1.55 |
| Basic (in shares) | 47.8M shares | 46.1M shares | 43.7M shares |
| Diluted (in shares) | 48.6M shares | 46.1M shares | 43.7M shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $33.0M | $91.5M | |
| Available-for-sale securities, current portion | $55.9M | $9.2M | |
| Accounts receivable, trade, net of allowance for credit losses of $22 and $152 as of December 31, 2025 and December 31, 2024, respectively | $8.0M | $8.5M | |
| Inventories | $30.2M | $29.0M | |
| Prepaid expenses and other current assets | $9.5M | $6.0M | |
| Current assets, discontinued operations | $0 | $4.6M | |
| Total current assets | $136.6M | $148.8M | |
| Property and equipment, net | $14.7M | $6.0M | |
| Operating lease right-of-use assets, net | $7.5M | $10.6M | |
| Other assets | $3.0M | $373.0K | |
| Available-for-sale securities, long term | $31.2M | $4.6M | |
| Equity investments | $0 | $995.0K | |
| Intangible assets, net | $4.3M | $5.6M | |
| Goodwill | $208.6M | $208.6M | |
| Long-term assets, discontinued operations | $0 | $14.1M | |
| Total assets | $405.9M | $399.5M | |
| Accounts payable | $1.5M | $3.4M | |
| Accrued expenses and other current liabilities | $12.0M | $12.1M | |
| Sales taxes payable | $2.3M | $4.2M | |
| Lease liabilities, operating, current portion | $2.2M | $1.5M | |
| Debt, current portion | $5.0M | $10.9M | |
| Current liabilities, discontinued operations | $0 | $616.0K | |
| Total current liabilities | $23.0M | $32.7M | |
| Lease liabilities, operating, long-term | $10.7M | $12.6M | |
| Debt, long-term | $0 | $5.0M | |
| Deferred tax liabilities | $189.0K | $124.0K | |
| Other long-term liabilities | $171.0K | $0 | |
| Long-term liabilities, discontinued operations | $0 | $78.0K | |
| Total liabilities | $34.0M | $50.6M | |
| Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding as of December 31, 2025 and December 31, 2024 | $0 | $0 | |
| Common stock, $0.001 par value; 150,000,000 shares authorized, 48,198,928 and 46,906,765 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $48.0K | $47.0K | |
| Additional paid-in capital | $711.4M | $683.9M | |
| Accumulated other comprehensive loss, net of taxes | $132.0K | $24.0K | |
| Accumulated deficit | -$339.7M | -$335.1M | |
| Total shareholders equity | $371.9M | $348.9M | $337.7M |
| Total liabilities and shareholders equity | $405.9M | $399.5M | |
| Allowance for doubtful accounts | $22.0K | $152.0K | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, authorized (in shares) | 1.0M shares | 1.0M shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, authorized (in shares) | 150.0M shares | 150.0M shares | |
| Common stock, issued (in shares) | 48.2M shares | 46.9M shares | |
| Common stock, outstanding (in shares) | 48.2M shares | 46.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$4.6M | -$20.2M | -$68.0M |
| Impairment of intangible assets | $0 | $0 | $5.8M |
| Impairment of long-lived assets | $0 | $0 | $9.7M |
| Gain on settlement of Global Cooling escrow | $0 | $0 | -$5.1M |
| Depreciation | $2.3M | $5.2M | $7.1M |
| Amortization of intangible assets | $2.4M | $3.5M | $5.2M |
| Amortization of loan costs | $0 | $0 | $13.0K |
| Stock-based compensation | $23.0M | $30.9M | $33.2M |
| Non-cash lease expense | $1.9M | $424.0K | $404.0K |
| Deferred income tax expense (benefit) | $65.0K | -$64.0K | -$62.0K |
| Change in fair value of contingent consideration | $0 | $0 | -$2.2M |
| Change in fair value of equity investment and other | -$983.0K | $4.1M | $0 |
| Accretion of investments | -$736.0K | -$474.0K | -$1.3M |
| Loss on disposal of assets held for rent, net | $510.0K | $567.0K | $594.0K |
| Loss on disposal of property and equipment, net | $11.0K | $154.0K | $633.0K |
| IPR&D expense | $15.5M | $0 | $0 |
| Net gain on disposal of subsidiaries | -$10.3M | -$15.9M | $0 |
| Accounts receivable, trade, net | $264.0K | -$2.9M | $15.4M |
| Inventories | -$1.3M | $781.0K | -$8.6M |
| Prepaid expenses and other current assets | -$3.0M | -$2.4M | $137.0K |
| Accounts payable | -$2.1M | $26.0K | -$8.4M |
| Accrued expenses and other current liabilities | -$1.1M | $6.5M | $2.0M |
| Sales taxes payable | -$1.9M | -$973.0K | $1.3M |
| Warranty liability | $5.0K | -$528.0K | -$454.0K |
| Other | $264.0K | -$258.0K | $97.0K |
| Net cash provided by (used in) operating activities | $20.1M | $8.4M | -$12.5M |
| Purchases of property and equipment | -$9.5M | -$3.2M | -$6.4M |
| Purchases of assets held for rent | -$886.0K | -$2.1M | -$4.9M |
| Proceeds from sale of available-for-sale securities | $6.8M | $3.5M | $3.5M |
| Maturities of available-for-sale securities | $34.8M | $18.4M | $52.7M |
| Investment in available-for-sale securities | -$114.1M | -$18.4M | -$27.1M |
| Purchases of intangible assets | $0 | -$300.0K | $0 |
| Investment in IPR&D | -$10.2M | $0 | $0 |
| Investment in convertible promissory note | -$2.0M | $0 | $0 |
| Proceeds from sale of divested entities | $23.5M | $73.4M | $0 |
| Payments on divestiture of Global Cooling | $0 | -$13.0M | $0 |
| Net cash (used in) provided by investing activities | -$71.5M | $58.3M | $17.8M |
| Payments on term loan | -$10.0M | -$5.0M | -$300.0K |
| Payments on equipment loans | $0 | -$1.6M | -$198.0K |
| Issuance of common stock | $0 | $0 | $10.2M |
| Proceeds from exercise of common stock options | $18.0K | $202.0K | $507.0K |
| Proceeds from financed insurance premium | $0 | $2.1M | $2.6M |
| Payments on financed insurance premium | -$975.0K | -$2.4M | -$2.4M |
| Other | $33.0K | -$74.0K | $64.0K |
| Net cash (used in) provided by financing activities | -$10.9M | -$6.8M | $10.6M |
| Net (decrease) increase in cash and cash equivalents | -$62.3M | $59.9M | $15.9M |
| Effects of currency translation on cash and cash equivalents | $0 | $0 | $35.0K |
| Assets acquired under operating leases | $0 | $5.8M | $880.0K |
| Assets acquired under finance leases | $0 | $0 | $1.7M |
| Purchase of property and equipment not yet paid | $0 | $107.0K | $359.0K |
| Unrealized loss (gain) on available-for-sale securities | $108.0K | -$18.0K | -$56.0K |
| Unrealized gain on currency translation | $0 | $0 | -$12.0K |
| Non-cash acquisition of PanTHERA | $5.3M | $0 | $0 |
| Cashless issuance of SciSafe earnout shares | $0 | $0 | $2.3M |
| Returned shares from settlement of Global Cooling escrow | $0 | $0 | -$5.1M |
| Cash interest paid | $762.0K | $1.6M | $1.9M |
Former names
- CRYOMEDICAL SCIENCES INCOct 13, 1995 to Nov 14, 20022
Recent filings
- Oct 9, 2026EFFECT
- Oct 9, 2026EFFECT
- Oct 8, 20264
- Oct 8, 20264
- Oct 8, 20264
- Oct 8, 20264
- Oct 8, 20264
- Oct 8, 20264
- Oct 8, 20264
- Oct 8, 20264
- Oct 8, 20264
- Oct 8, 20264
- Oct 8, 20264
- Oct 6, 20268-K
- Oct 6, 202625-NSE
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10